MassChallenge Startups Create Impact

2,928

Startups Accelerated

$8.6B

Funding Raised

$3.6B

Revenue Generated

186K+

Jobs Created

Our startups

Be inspired. Search our startups.

Clear  
Oculogenex, Inc.

Geographic atrophy from macular degeneration is a leading cause of untreatable blindness in the aging population. Oculogenex is developing a patented treatment that can repair the aged and damaged retina, reprogram it to a youthful state, and prevent vision loss from degeneration. This therapy can potentially last a lifetime and is delivered into the eye with an injection. Our technology can restore quality of life and protect the independence of millions at risk of blindness worldwide.
Our novel gene therapy is being developed to restore central vision in patients with macular degeneration and improve their quality of life.

Connect with Oculogenex, Inc.

Oculogenex, Inc.

2021

2021 Gold BOS-96

2022 Finalist HT-113

Sub industry

Therapeutics (Pharma / Biotech)

Additional Industries
Public Health

Mission

Our mission is to equip bold entrepreneurs to disrupt the status quo and to create meaningful change.